Aelis Farma Announces Completion of Patient Randomization for Phase 2b Study with AEF0117 for the Treatment of Cannabis AddictionPosted by On

BORDEAUX, France–(BUSINESS WIRE)–Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain disorders, today announces to have reached a key milestone by successfully completing the recruitment of 333 patients suffering from cannabis addiction in its Phase 2b clinical study with AEF0117. AEF0117 is the first of a new class of proprietary drugs developed by Aelis Farma, the Signaling Spec

Source link


Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.